

Special Issue

Hepatocellular Carcinoma in the Era of Precision Oncology

Message from the Guest Editors

Great strides have been made in the management of hepatocellular carcinoma, but this condition remains a significant challenge due to its aggressiveness and complexity. The therapeutic options have been expanded thanks to studies on the pathways of carcinogenesis and disease progression. Early diagnosis is still key, as one of the main negative prognostic factors of advanced disease. The search for specific, accurate, and easily and minimally obtainable biomarkers such as circulating DNA and the identification of immunological pathways and bidirectional multiorgan pathways (e.g., gut–liver axis) with metabolites that can be utilized for diagnostic purposes are significantly changing the management of HCC. The introduction of new systemic pharmacological therapies and the use of ablative therapies that are not new but that have aroused particular interest for the discovery of systemic effects are further shifting the field thanks to the possibility of new tailor-made and customizable therapeutic combinations that are helping to expand and greatly improve the therapeutic possibilities in the context of the new emerging discipline of precision oncology.

Guest Editors

Dr. Anna Rossetto

General Surgery, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), San Daniele del Friuli, Udine, Italy

Prof. Dr. Alessandro Uzzau

Department of Experimental and Clinical Medical Sciences, Università degli Studi di Udine, Udine, Italy

Deadline for manuscript submissions

closed (15 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/156278

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).